Glaucoma Clinical Trials 2024

What are the top hospitals conducting glaucoma research?

When it comes to advancing the field of ophthalmology and finding new treatments for glaucoma, several leading hospitals are making great strides. In Newport Beach, California, the Eye Research Foundation is dedicated to conducting research on this sight-threatening condition. With four active glaucoma trials currently underway and a total of 17 completed trials in their history, this foundation has been at the forefront of glaucoma research since their first recorded trial in 2007.

Similarly committed to advancing knowledge about glaucoma is Coastal Research Associates, LLC in Roswell, Georgia. This institution also boasts four ongoing clinical trials focused on finding innovative solutions for patients with glaucoma. Since initiating their first trial in 2010, they have conducted a commendable total of 16 studies dedicated to this eye disease.

Moving across the country to Boston's Massachusetts Eye and Ear hospital reveals another hub for groundbreaking research on glaucoma. Although relatively newer compared to other institutions listed here with only three ongoing clinical trials and three completed ones thus far as they began researching just last year in2021; however,the expertise housed within its walls promises significant contributions towards understanding this complex condition.

In Durham's Duke Eye Center too endeavors around similar lines can be witnessed where current investigations count up-to-three simultaneously being held while having previously carried out twelve such experiments starting from back whenit recordedits veryfirst examinationinthe yeartwo thousand thirteen.Across America at Stanford University's Byers Eye Institute located within Palo Alto emerges three active clinical tests concerningglaucomawhile counting five former examinationsfrom twothousand sixteen onwards.Most impressively- these figures prove that even smaller-scale projects are capable of driving impactful progress in tacklingthis silent thiefof vision.

These hospitals represent beacons of hope for those affected by glaucoma – a disease that silently steals sight if left untreated or undertreated.The dedication demonstratedby these prestigious medical establishmentsreiteratesthe importance of clinical trials in findingmore effective treatments,improving patient outcomes,and ultimately ensuring a brighter future for millions affected by this condition.

Which are the best cities for glaucoma clinical trials?

When it comes to glaucoma clinical trials, several cities have emerged as leaders in research and development. Among them are New york, San Antonio, Newport Beach, Boston, and Philadelphia. These cities collectively host a significant number of active trials focused on studying various treatments for glaucoma. From Rho-Kinase Inhibitors to Nicotinamide and Pyruvate interventions, Bimatoprost SR to ELIOS Procedures, AGN-193408 SR to Low Energy SLT techniques—these trials explore innovative approaches that hold promise for improving the management and treatment of glaucoma. With multiple ongoing studies in each city, individuals with glaucoma can find opportunities to participate in cutting-edge clinical trials that could potentially revolutionize glaucoma care.

Which are the top treatments for glaucoma being explored in clinical trials?

Glaucoma research is at the forefront of medical innovation, with several exciting treatments currently under exploration in clinical trials. Leading the charge is the Rho-Kinase Inhibitor, which has shown great promise in two active glaucoma trials since its initial listing in 2014. Another notable contender is sulcus tube placement, a novel treatment option that has already garnered interest with one ongoing trial and first listed just this year in 2023. As researchers delve deeper into these cutting-edge therapies, they bring us closer to revolutionizing glaucoma care and improving outcomes for patients worldwide.

What are the most recent clinical trials for glaucoma?

Exciting advancements are being made in the realm of glaucoma treatment, with several recent clinical trials offering promising prospects. One notable trial involves H-1337 0.6% Ophthalmic Solution administered twice daily for individuals with glaucoma. Another study focuses on Phase 1 Cohort B, which explores potential treatments through a combination of Phase 1 and Phase 2 testing. Additionally, researchers are investigating the effectiveness of a Latanoprost contact lens and topical insulin as potential therapies for glaucoma patients. Lastly, a trial involving Nicotinamide and Pyruvate is underway to evaluate their efficacy in treating this condition across Phases 2 and 3. These ongoing studies provide hope that improved management options for glaucoma may soon be within reach.

What glaucoma clinical trials were recently completed?

Several recently completed clinical trials have contributed to the advancement of glaucoma research. In October 2021, Qlaris Bio, Inc. successfully concluded trials for both QLS-101 ophthalmic solution 2% and Test - Bimatoprost 0.01% Ophthalmic Solution. The same month also saw the completion of a trial sponsored by Mankind Pharma Limited, testing TRS01 as a potential treatment option. Furthermore, Qlaris Bio, Inc.'s study on QLS-101 reached its conclusion in September 2021. These significant advancements hold promise for enhancing our understanding and management of glaucoma while offering hope to those affected by this debilitating condition.